FDC vs GLAND: Stock Comparison

FDC Limited vs Gland Pharma Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Gland Pharma Limited is the larger company by market capitalisation. FDC Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Gland Pharma Limited shows faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of FDC Limited and Gland Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, FDC is more favourable on 8 of 13 scored metrics and GLAND on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
GLAND is the larger company
₹39,200 Cr vs ₹6,606 Cr
P/E Ratio
FDC has a lower P/E
23.92x vs 38.29x
P/B Ratio
FDC has a lower P/B
2.71x vs 3.8x
EPS
GLAND has higher earnings per share
₹62.31 vs ₹17.27
Dividend Yield
FDC has a higher dividend yield
2.42% vs 0.81%
Revenue Growth (TTM YoY)
GLAND has faster revenue growth
22.3% vs 18.9%
EPS Growth (TTM YoY)
FDC has faster EPS growth
166.8% vs 96.4%
Qtr Sales Growth
GLAND has stronger quarterly sales growth
22.3% vs 18.9%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricFDCGLAND
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricFDCGLAND
Live Price₹412.95₹2,379.8
Day Change2.92%0.09%
Volume96,7781.57 L
52-Week High₹527.8₹2,573.5
52-Week Low₹312.95₹1,573.6
Distance from 52W High-21.76%-7.53%

Valuation

MetricFDCGLAND
Market Cap₹6,606 Cr₹39,200 Cr
P/E Ratio23.92x38.29x
P/B Ratio2.71x3.8x
EPS₹17.27₹62.31
Book Value₹152.62₹628.81
Dividend Yield2.42%0.81%

Growth

MetricFDCGLAND
Revenue Growth (TTM YoY)18.9%22.3%
EPS Growth (TTM YoY)166.8%96.4%
Qtr Sales Growth18.9%22.3%
Qtr Profit Growth167%96.6%

Profitability & Leverage

MetricFDCGLAND
ROE12.5%10.7%
ROCE16.7%15.1%
Net Margin12.96%16.18%
Operating Margin15.9%25.3%
Debt to Equity0.01x0.03x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricFDCGLAND
Promoter Holding69.66%51.83%
FII Holding1.4% 1 pp8.74% 1.44 pp
DII Holding6.31% 0.02 pp30.44% 2.91 pp
Public Holding22.63% 0.98 pp9.05% 1.53 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: FDC Limited and Gland Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.